Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1452795 | 0.93 | LTA4H (0.36) | LTA4HRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1453476 | 0.85 | LTA4H (0.33) | LTA4HRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1454411 | 0.80 | PDCD1 (0.34) | SMN1; SMN2MAPK1TDP1KDM4E | |
| SCHEMBL1453194 | 0.79 | RAB9A (0.33) | LTA4HRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1452577 | 0.79 | RAB9A (0.37) | LTA4HRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1452236 | 0.79 | CYP11B1 (0.31) | — | |
| SCHEMBL1452923 | 0.78 | LTA4H (0.33) | LTA4HRAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1453851 | 0.77 | TACR1 (0.31) | — | |
| SCHEMBL1452870 | 0.76 | HTR2A (0.42) | SMN1; SMN2TDP1ALDH1A1KDM4E | |
| SCHEMBL1452155 | 0.75 | ALDH1A1 (0.33) | NPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | LTA4H 4290/4885RAB9A 3323/4885SMN1; SMN2 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.